Incyte stock gains support from a 36 percent surge
Published on 09/08/2026 at 13:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Incyte stock (US45337C1027) is trading at USD 102.58, and Morningstar puts the market capitalization at USD 20.14 billion with a previous close of USD 100.92 on September 8, 2026.
Growth still frames the story
A recent update on Seeking Alpha says the shares have surged 36 percent since March 2026, while the S&P 500 rose 15 percent over the same stretch. That is the clearest quantified comparison in the current stream.
Morningstar also shows a 52-week range of USD 53.56 to USD 112.29, so the stock now sits above that listed high in the snapshot that was available on September 8, 2026.
Valuation stays in view
The same Morningstar snapshot lists a normalized P/E ratio of 15.98 and a price-to-sales ratio of 4.29. For investors, that mix keeps valuation and pipeline expectations tied closely together.
Morningstar describes Incyte as a biotechnology company focused on small-molecule drugs, with Jakafi as a leading product and Opzelura as its first dermatology product. The business mix still leans on oncology and dermatology franchises.
Product base matters
Jakafi treats two rare blood cancer indications and graft versus host disease, while Opzelura was approved in 2021 for atopic dermatitis and in 2022 for vitiligo. Those products remain central to the company's revenue base and market reading.
Stock level and market view
Incyte stock trades at USD 102.58 as of September 8, 2026, with a market capitalization of USD 20.14 billion and a prior close of USD 100.92. The price is now close to the upper half of its 52-week band.
Incyte stock overview
- Company: Incyte Corporation
- ISIN: US45337C1027
- Ticker: INCY
- Trading venue: Nasdaq
- Price (as of September 8, 2026): USD 102.58
- Market capitalization: USD 20.14 billion
- Sector / Industry: Healthcare / Biotechnology
